# QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.

> **NCT06749899** · PHASE3 · RECRUITING · sponsor: **Sun Yat-Sen University Cancer Center** · enrollment: 580 (estimated)

## Conditions studied

- Nasopharyngeal Cancinoma (NPC)
- Nasopharyngeal Cancer

## Interventions

- **DRUG:** QL1706
- **DRUG:** Gemcitabine
- **DRUG:** Cisplatin
- **RADIATION:** Intensity-modulated radiotherapy

## Key facts

- **NCT ID:** NCT06749899
- **Lead sponsor:** Sun Yat-Sen University Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-04
- **Primary completion:** 2028-12-01
- **Final completion:** 2030-12-01
- **Target enrollment:** 580 (ESTIMATED)
- **Last updated:** 2025-05-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06749899

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06749899, "QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT06749899. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*